SALT LAKE CITY, UT and TORONTO, ON--(Marketwired - Jun 9, 2015) - EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, has announced that Impex Healthcare (www.ImpexHealthcare.com) will commence the distribution and marketing of one of the company's natural products, Glucora, in Bangladesh along with future distribution of other glucose management products.
Glucora is a soft capsule product that provides support for healthy glucose metabolism. Glucora contains natural ingredients in a highly efficient self-nanoemulsifying composition. Information on the product is available online at www.nano-essentials.com.
Impex Healthcare (www.ImpexHealthcare.com) is a company based in Dhaka, Bangladesh that is engaged in the import, marketing and distribution of various innovative healthcare products in Bangladesh. The Impex product line includes supplements (dietary and women health-related), medical devices and raw materials.
With the population of approximately 150 million, the prevalence of diabetes amongst adult population aged 20 to 79 had more than doubled in Bangladesh -- from 4% in 1995-2000 to 9% in 2006-2000 according to 2014 International Diabetes Federation World Atlas. Same source predicts Bangladesh to take the 8th spot in the world in terms of diabetic population by 2030 with 10.4 million people afflicted.
"We are pleased to have an initial footprint in the growing diabetes population in Bangladesh," says Anna Gluskin, EastGate's CEO. "Glucora will serve this marketplace well in terms of providing a solution for natural glucose management. We look forward to expanding the distribution to other potential glucose management products," continues Ms. Gluskin.
Cautionary statement on forward-looking information
All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, including the provisions for "safe harbour" under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.
The words "anticipates," "plans," "expects," "indicate," "intend," "scheduled," "estimates," "forecasts," "focus," "guidance," "initiative," "model," "methodology," "outlook," "potential," "projected," "pursue," "strategy," "study," "targets," or "believes," or variations of or similar such words and phrases or statements that certain actions, events or results "may," "could," "would," or "should," "might," or "way forward," "will be taken," "will occur" or "will be achieved" and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.